Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a biopharmaceutical royalty company focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines. Our primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products, allowing us to generate long-duration, non-dilutive cash flows supported by a lean corporate cost structure.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Business segments
Q1 2026 · $50.6MThe company’s own SEC segment disclosure.
- Financial Royalty Assets$10.0M20%
- Material Sales Captisol$8.7M17%
- Kyprolis$6.7M13%
- QARZIBA$6.3M12%
- Royalty Intangible Other$3.8M7%
- Rylaze$3.2M6%
- Other (9)$11.9M24%
Ligand Pharmaceuticals Incorporated (LGND) reported revenue of $64M in Q2 2026 (quarter ended June 30, 2026), up 34% from the same quarter a year earlier. That came with net income of $49M (76% of revenue). For the full year FY2025, revenue was $268M (+60% year on year) and net income $124M. Its largest product in 2026-Q1 was Financial Royalty Assets at $10M, 20% of the disclosed total, just ahead of Material Sales Captisol at 17%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.